Potential for subsets of wt-NPM1 primary AML blasts to respond to retinoic acid treatment

Acute myeloid leukemia (AML) has high mortality rates, perhaps reflecting a lack of understanding of the molecular diversity in various subtypes and a lack of known actionable targets. There are currently 12 open clinical trials for AML using combination therapeutic modalities including all-trans re...

Descripción completa

Detalles Bibliográficos
Autores principales: Bunaciu, Rodica P., MacDonald, Robert J., Gao, Feng, Johnson, Lynn M., Varner, Jeffrey D., Wang, Xin, Nataraj, Sarah, Guzman, Monica L., Yen, Andrew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5790527/
https://www.ncbi.nlm.nih.gov/pubmed/29423110
http://dx.doi.org/10.18632/oncotarget.23642

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5790527/
https://www.ncbi.nlm.nih.gov/pubmed/29423110
http://dx.doi.org/10.18632/oncotarget.23642

Ejemplares similares